National Institutes of Health Clinical Center (CC)
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Estimate the maximum tolerated dose (MTD) of imetelstat given as a 2-hour IV infusion on D1 and D8 every 21 days.
Define the toxicities and characterize pharmacokinetics
To define antitumor effects and to assess the biological activity by assessing telomerase activity, telomere length, hTERT protein, hTERT mRNA and hTR levels; hTERT expression and protein, telomere length, hTERT mRNAS and hTR levels in tumor.
1 Year to 21 Years (Child, Adult)
April 2, 2012
November 21, 2012
† Study has passed its completion date and status has not been verified in more than two years.